Posted by Michael Wonder on 06 Jun 2018
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
6 June 2018 - It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
NICE has published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic model “did not accurately reflect the treatment pathway” for these patients.
It noted that data comparing the clinical effectiveness of Zytiga (abiraterone) plus androgen deprivation therapy (ADT) with current standard treatment (docetaxel plus ADT) “has not been fully explored” and so there is “no plausible cost-effectiveness estimate” comparing the two.
